# Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

> **NCT07011849** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Renal Cell Carcinoma
- Brain Metastasis

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07011849
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-04
- **Primary completion:** 2025-08-07
- **Final completion:** 2025-08-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011849, "Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07011849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*